Maya Dadiani, PhD
Email: maya.dadiani@sheba.health.gov.il
Phone: 03-5307132
Position: Research head
Areas of Expertise: Breast Cancer, Genomics, computational biology, microbiome
LinkedIn
Find me on Twitter: @MayaDadiani
Research Interests:
Breast Cancer, Cancer Genomics and Genetics, Tumor evolution, Resistance to treatment, Tumor and gut microbiome in cancer, Tumor microenvironment, MRI of breast cancer
Education:
2011, Postdoctoral training – Computational Biology – Weizmann Institute of Science, Rehovot, Israel
2007, Ph.D., Weizmann Institute of Science, Rehovot, Israel
2002, M.Sc., Weizmann Institute of Science, Rehovot, Israel
1999, B.Sc – Biology, Hebrew University, Jerusalem, Israel
Affiliations:
2012, Lab of Breast Cancer Translational Research, Cancer Research Center, Sheba Medical Center, Tel Hashomer, Israel
Honors & Awards:
2018, ELROV fund - Sheba Innovation Center Award
2018, The Nehemia Rubin Excellence in Biomedical Research – The TELEM Program, supported by the Aaron Gutwirth Fund
2016, EACR - European Association for Cancer Research - poster prize
2015, Cancer Biology Research Center, TAU – Outstanding scientific work
2014, Israeli society for Cancer Research – ISCR best abstract award
2012, IMPAKT breast cancer conference – Brussels, Belgium, best abstract.
2008, Dean Fellowship, Department of computer science, Weizmann Institute of Science
2007, Suzan G. Komen for the Cure Award, AACR
2003, 2004, 2006, Travel stipends, International Society for Magnetic Resonance in Medicine
2003, Avon Foundation Award, AACR
2003, Katzir Scholarship for PhD travel stipend, Weizmann Institute of Science
2002, AstraZeneca Scholar-in-Training Award, AACR
Research grants:
2023-2024, Sheba-Bar-Ilan joint grans, Exploring tumor-bacteria interplay in breast cancer by spatial transcriptomics
2023, Sheba 2nd chance, Exploring the human breast cancer intra-tumor microbiome and its clinical significance
2021-2022, Israel Cancer Association, Exploring the clinical significance of the human breast cancer intra-tumor microbiome
2019-2021, Sheba Research fund, Mapping personalized resistance to chemotherapy in breast cancer to predict response
2019-2020, Israel Cancer Association, Subtype switch between primary and recurrent breast cancer: the underlying molecular mechanism and therapeutic implications
2018-2023, Sheba, The Nehemia Rubin Excellence in Biomedical Research – The TELEM Program, supported by the Aaron Gutwirth Fund
2018-2019, Israel Cancer Research Fund (ICRF), The role of Intestinal Microbiota in Breast Cancer Progression and Therapy
2018, Sheba Innovation Center, award Estimation of Peritumoral Interstitial Fluid Flow Velocity
2016-2017, AusiMed, Deciphering the Molecular Mechanisms Underlying Treatment Response & Impact on Outcome in BRCA Mutation Carriers with Triple Negative Breast Cancer
2015-2016, Israel Cancer Research Fund (ICRF), Patterns of Molecular Evolution through the Course of Disease in Recurrent Breast Cancer
2014-2017, Ministry of Science Israel, A proteogenomic analysis of the response to chemotherapy in breast cancer
2013-2014, Israel Cancer Association, Tumor Evolution Throughout the Neoadjuvant Chemotherapy Timeline in Recurrent Breast Cancer: Profiling Expression Patterns and Genetic Signatures
Publications:
Here is a link to the publications of Dr. Maya Dadiani
